Piramal Pharma FY27 outlook: mid-teens growth, ADC push

What changed in the FY27 narrative

Piramal Pharma is positioning FY27 as a recovery year, with Chairperson Nandini Piramal pointing to a pickup in order discussions and complex drug demand that could lift profitability over the next few years. The company expects early-to-mid teens revenue growth in FY27, and indicated that EBITDA could eventually outpace revenue growth as operating leverage improves. The near-term focus is on segments where it believes demand is strengthening, especially contract manufacturing linked to complex therapies.

A key part of the updated narrative is the link between biotech funding and client activity. Piramal said higher funding is translating into more requests for proposals (RFPs) and better order inflows, helping the company exit FY26 with stronger momentum. It also highlighted a shift in customer interest towards targeted therapies such as antibody-drug conjugates (ADCs), rather than weight-loss drugs.

Biotech funding and RFP momentum

Nandini Piramal said biotech funding in the second half of FY26 was about 80% higher than the second half of last year, and that this is now translating into higher RFPs and order inflows. In the same discussion, she also referenced overall US biotech funding growth of 18% in the second half of FY26, while reiterating the company’s stronger funding-linked momentum. The company’s takeaway is that stronger funding conditions tend to move through a pipeline of RFPs, project wins, and ramp-ups.

This matters for Piramal Pharma because its contract development and manufacturing organisation (CDMO) platform depends on a steady flow of early and mid-stage projects that can scale into commercial supply. Management linked FY27 growth expectations to this improvement in funnel activity and to a stronger exit from FY26.

CDMO rebound and the shift to complex, targeted therapies

Piramal Pharma said rising demand for complex drugs is supporting contract manufacturing, with ADCs singled out as a growth driver. ADCs are targeted cancer therapies, and the company described them as a differentiated offering within its CDMO operations. Management also indicated that the ADC opportunity is not limited to a single geography, describing growth as broad-based across the US, the UK, and India.

The company expects its ADC-related business, including payload and linker work done out of Riverview, to contribute to growth in FY27. It also flagged growth from its injectable pain franchise as it works with CDMOs, alongside incremental contribution from newly acquired products.

Canalog acquisition and portfolio expansion

Piramal Pharma completed the acquisition of a new product, Canalog, effective April 1, and expects it to add to revenue and EBITDA for the year. The company framed this as part of a broader plan to expand the product portfolio while continuing to pursue organic growth.

Alongside portfolio moves, management reiterated that it is investing in facility expansion and cost optimisation to support growth and sustain EBITDA margins. The company also highlighted hospital generics as a strategic area, with a focus on complex hospital products.

Facility investments and approvals: Digwal, Lexington, Riverview

Piramal said it invested in its Digwal facility over the last year and has been receiving regulatory approvals steadily throughout the year, with additional approvals expected. The facility was created to compete in targeted markets, and the company expects growth as these capabilities scale.

Separately, Piramal said it is investing US$10 million to expand two US facilities in Lexington and Riverview. The Lexington capability is expected to come online in 2027 and is described as important for the company’s integrated ADC development and manufacturing programme. In addition, one report cited a 70% capacity increase at the Grangemouth facility as part of expansion efforts.

India Consumer Healthcare: growth ahead of market

Piramal said its consumer healthcare portfolio is doing well, with brands growing ahead of the market at 17%. Management said it expects this business to continue to grow and add to profitability.

The company operates across three verticals: Piramal Pharma Solutions (CDMO), Piramal Critical Care (complex hospital generics), and India Consumer Healthcare (over-the-counter products). It has also said around 69% of revenue comes from regulated markets such as the US, UK, Europe, and Japan, and that future growth will be balanced between India, the US, and the UK.

Key numbers investors tracked

The company reported a net loss of ₹82 crore in Q1 FY26 versus a net loss of ₹89 crore a year earlier. EBITDA margin for Q1 FY26 was 9% versus 11% in Q1 FY25, with the company attributing the impact primarily to inventory destocking, partly offset by improved profitability at overseas CDMO facilities.

On leverage, management said net debt to EBITDA is 3.6, and expects it to remain range-bound as it continues growth and maintenance capex. The company also disclosed it used ₹477.46 crore for investing activities, a year-on-year increase of 10.01%.

Stock move, return profile, and valuation signals

Piramal Pharma’s share price rose 1.56% from its previous close of ₹153.81, last trading at ₹156.20 in the cited update. The stock’s reported returns were: 1 week 5.9%, 1 month 17.21%, 3 months 3.16%, 1 year -30.15%, and 3 years 110.65%.

On valuation, one set of analysts kept their fair value estimate unchanged at ₹200.10, while another narrative update maintained a fair value estimate of ₹204.6 per share, citing unchanged assumptions on discount rate, revenue growth, profit margin, and future P/E. A separate brokerage note cited (as of August 20, 2025) a CMP of ₹192 with a target of ₹270 over 12 months.

Forecasts: growth expectations and profitability path

Piramal Pharma is forecast to grow earnings by 84.5% per annum and revenue by 11.4% per annum, with EPS expected to grow by 84.43% per annum. Return on equity is forecast to be about 8.1% in three years (also cited as 8.05% in the same dataset). It is forecast to become profitable over the next three years, described as faster than the savings rate (6.9%) and above average market growth.

Revenue growth of 11.4% per year was also described as slightly faster than the Indian market’s 11.2% per year, while still below a “high growth” threshold of 20%.

Snapshot table: facts mentioned in the updates

Why this matters for investors

The core takeaway is that Piramal’s FY27 expectations lean on two measurable drivers: improving RFP and order inflow momentum, and scaling of complex therapy manufacturing such as ADCs. The company is also pairing the demand narrative with facility expansion and product portfolio actions, including Canalog, which it expects to contribute to both revenue and EBITDA.

At the same time, the data points in circulation show a mixed base: recent profitability remains under pressure (Q1 net loss and margin compression), leverage remains elevated (net debt to EBITDA at 3.6), and forecast ROE is still described as low at about 8.1% in three years. For the market, the near-term monitoring points are whether the stronger funding environment continues to translate into executable orders, and whether the expanded network (Digwal approvals, Lexington and Riverview investments) supports margin improvement.

Conclusion

Piramal Pharma is setting expectations for a FY27 rebound with early-to-mid teens revenue growth and improving margins, anchored by complex drug CDMO demand, ADC opportunities, and incremental contributions from Canalog. Investors will track execution across facility ramps, regulatory approvals, and order conversion from the higher RFP pipeline, while watching leverage and profitability trends as capex continues.